• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于肿瘤受体显像的锝标记促黄体生成素释放激素

Tc-LHRH in tumor receptor imaging.

作者信息

Hao Dawei, Sun Lingfei, Hu Xiang, Hao Xiaowen

机构信息

Department of Radiotherapy, Xuzhou Central Hospital, Xuzhou, Jiangsu 221009, P.R. China.

出版信息

Oncol Lett. 2017 Jul;14(1):569-578. doi: 10.3892/ol.2017.6246. Epub 2017 May 24.

DOI:10.3892/ol.2017.6246
PMID:28693207
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5494691/
Abstract

Detection of gonadotropin-releasing hormone (GnRH) also known as luteinizing hormone-releasing hormone (LHRH) in the relevant tumor tissue and normal tissues and organs expression was investigated. To examine the method of direct radio labeling of LHRH by Tc with relatively high radiochemical purity and stability, screening the best labeling conditions, to establish a simple and reliable method of preparation of Tc-LHRH was undertaken. The detection of radioisotope-labeled LHRH distribution in mice, LHRH receptor imaging for the study and treatment of cancer basis were evaluated. i) Immunohistochemical staining test was used in 23 patients with hepatocellular carcinoma (HCC), 20 patients with breast cancer, 10 patients with prostate cancer, 20 patients with lung cancer, 20 patients with endometrial cancer tumor cells and normal tissue LHRH-R De Biaoda levels; ii) pre-tin method use direct labeling of LHRH, marking completion of saline or human serum were added at room temperature, the chromatography was measured at different times, to calculate the rate of labeled product and the radiochemical purity of the label, observation of its stability, and comparative analysis of selected optimal condition; iii) rat pituitary cell membrane protein, the product of radio-receptor marker analysis, through the saturation and inhibition experiments, was used to test its receptor binding activity; iv) Ch-T method labeled I-LHRH, tail vein injection of normal mice at different times were sacrificed, blood and major organs were determined and calculated per gram organization percentage injected dose rate (%, ID/g). Detected by immunohistochemistry in 23 cases of HCC in the LHRH-positive rate was 82.61%, in the corresponding normal tissues, the positive rate was 15%; 20 cases of breast cancer positive rate of 95%, the corresponding normal tissues, the positive rate was 20%; 10 cases of prostate cancer positive rate of 70%, the corresponding normal tissues, the positive rate of 40%; 20 cases of lung cancer positive rate of 85%, the corresponding normal tissues, the positive rate of 15.79%; 20 cases of endometrial cancer positive rate of 80% in the corresponding normal tissues was 16.67% positive. Tc-LHRH mark was 97.9-100.0%, the radiochemical purity of 93.9-96.4%, marking the reaction gel content of <5%. Great product receptor marker analysis showed Tc-LHRH with saturable receptor binding characteristics and inhibition, and high affinity, RT = 23.2174 pmol, KD = 0.4348 nmol; intravenous injection of I-LHRH within 72 h after the mice rapidly cleared the blood radioactivity, the major radioactive accumulation in the liver and kidneys and by the liver, renal clearance, and other tissues and organs of the radioactivity gradually decreased with time. In conclusion, i) the liver, lung, breast, prostate, endometrial cancer exist in both LHRHR; ii) Tc-LHRH preparation is simple, rapid, radiochemical purity product obtained higher marks, better stability, no further purification; and iii) LHRH Tc labeled, still has a high receptor binding ability, biological activity; and has an ideal and realistic dynamics in animals, there is hope, as with the clinical value of imaging agent of GnRH receptors.

摘要

研究了促性腺激素释放激素(GnRH)又称促黄体生成素释放激素(LHRH)在相关肿瘤组织及正常组织和器官中的表达情况。为研究用锝直接放射性标记LHRH的方法,该方法具有较高的放射化学纯度和稳定性,筛选最佳标记条件,建立一种简单可靠的锝- LHRH制备方法。评估放射性同位素标记的LHRH在小鼠体内的分布检测情况,为研究和治疗癌症的LHRH受体显像奠定基础。i)采用免疫组化染色检测23例肝细胞癌(HCC)、20例乳腺癌、10例前列腺癌、20例肺癌、20例子宫内膜癌患者肿瘤细胞及正常组织中LHRH-R的表达水平;ii)采用预锡法直接标记LHRH,标记完成后于室温下加入生理盐水或人血清,在不同时间进行层析测定,计算标记产物的标记率和放射化学纯度,观察其稳定性,并进行比较分析以选择最佳条件;iii)用大鼠垂体细胞膜蛋白进行放射受体标记分析产物,通过饱和及抑制实验检测其受体结合活性;iv)采用Ch-T法标记I-LHRH,尾静脉注射正常小鼠后在不同时间处死,测定血液及主要脏器放射性,并计算每克组织注射剂量率(%,ID/g)。免疫组化检测显示,23例HCC中LHRH阳性率为82.61%,相应正常组织中阳性率为15%;20例乳腺癌阳性率为95%,相应正常组织中阳性率为20%;10例前列腺癌阳性率为70%,相应正常组织中阳性率为40%;20例肺癌阳性率为85%,相应正常组织中阳性率为15.79%;20例子宫内膜癌阳性率为80%,相应正常组织中阳性率为16.67%。锝- LHRH标记率为97.9 - 100.0%,放射化学纯度为93.9 - 96.4%,标记反应凝胶含量<5%。放射受体标记分析显示锝- LHRH具有可饱和的受体结合特性及抑制作用,且亲和力高,RT = 23.2174 pmol,KD = 0.4348 nmol;静脉注射I-LHRH后72 h内小鼠血液放射性迅速清除,主要放射性积聚于肝脏和肾脏并经肝、肾清除,其他组织器官放射性随时间逐渐降低。综上所述,i)肝癌、肺癌、乳腺癌、前列腺癌、子宫内膜癌组织中均存在LHRHR;ii)锝- LHRH制备方法简单、快速,所得标记产物放射化学纯度较高,稳定性较好,无需进一步纯化;iii)锝标记的LHRH仍具有较高的受体结合能力和生物活性;且在动物体内具有理想的动力学表现,有望作为GnRH受体显像剂应用于临床。

相似文献

1
Tc-LHRH in tumor receptor imaging.用于肿瘤受体显像的锝标记促黄体生成素释放激素
Oncol Lett. 2017 Jul;14(1):569-578. doi: 10.3892/ol.2017.6246. Epub 2017 May 24.
2
[Preparation of (99m)Tc-EDTA-MN and Its Bioimaging in Mouse].(99m)Tc-EDTA-MN 的制备及其在小鼠体内的生物成像
Zhongguo Fei Ai Za Zhi. 2015 Jul;18(7):422-6. doi: 10.3779/j.issn.1009-3419.2015.07.06.
3
Evaluation of a New Tc-labeled GnRH Analogue as a Possible Imaging Agent for Prostate Cancer Detection.评估一种新型 Tc 标记 GnRH 类似物作为前列腺癌检测的潜在成像剂。
Anticancer Agents Med Chem. 2020;20(14):1695-1703. doi: 10.2174/1871520620666200619175352.
4
Biodistribution and preparation of technetium-99m-labeled D-D₃ monoclonal antibody against pro-gastrin-releasing peptide (₃₁₋₉₈) in mice.放射性核素标记 D-D₃ 单克隆抗体 against pro-gastrin-releasing peptide (₃₁₋₉₈) 在小鼠体内的生物分布与制备。
Chin Med J (Engl). 2013 Apr;126(7):1333-6.
5
[(99m)Tc radiolabeling of a novel polypeptide molecular probe for lung cancer and its biodistribution in animals].[一种新型肺癌多肽分子探针的(99m)Tc放射性标记及其在动物体内的生物分布]
Nan Fang Yi Ke Da Xue Xue Bao. 2013 Aug;33(8):1169-72.
6
Ability of luteinizing hormone releasing hormone-Pseudomonas aeruginosa exotoxin 40 binding to LHRH receptor on human liver cancer cells.促黄体生成素释放激素-铜绿假单胞菌外毒素40与人肝癌细胞上促黄体生成素释放激素受体的结合能力。
World J Gastroenterol. 2004 Oct 1;10(19):2870-3. doi: 10.3748/wjg.v10.i19.2870.
7
Preparation and Identification of HER2 Radioactive Ligands and Imaging Study of Breast Cancer-Bearing Nude Mice.HER2放射性配体的制备与鉴定及荷人乳腺癌裸鼠的成像研究
Transl Oncol. 2017 Aug;10(4):518-526. doi: 10.1016/j.tranon.2017.04.003. Epub 2017 May 27.
8
[Radio-labeling of T7 peptide with 99mTc and its biodistribution in nude mice bearing non-small cell lung cancer].[用99mTc对T7肽进行放射性标记及其在荷非小细胞肺癌裸鼠体内的生物分布]
Zhongguo Fei Ai Za Zhi. 2014 Mar;17(3):189-96. doi: 10.3779/j.issn.1009-3419.2014.03.02.
9
Kit preparation and biokinetics in women of 99mTc-EDDA/HYNIC-E-[c(RGDfK)]2 for breast cancer imaging.用于乳腺癌成像的99mTc-EDDA/HYNIC-E-[c(RGDfK)]2在女性中的试剂盒制备及生物动力学研究
Nucl Med Commun. 2014 Apr;35(4):423-32. doi: 10.1097/MNM.0000000000000065.
10
More advantages in detecting bone and soft tissue metastases from prostate cancer using F-PSMA PET/CT.使用F-PSMA PET/CT检测前列腺癌骨和软组织转移方面有更多优势。
Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.

引用本文的文献

1
Deciphering Aflatoxin B1 affected critical molecular pathways governing cancer: A bioinformatics study using CTD and PANTHER databases.解析黄曲霉毒素B1影响癌症的关键分子途径:一项使用CTD和PANTHER数据库的生物信息学研究
Mycotoxin Res. 2025 Feb;41(1):93-111. doi: 10.1007/s12550-024-00563-0. Epub 2024 Oct 17.
2
Therapeutic dosing and targeting efficacy of Pt-Mal-LHRH towards triple negative breast cancer.Pt-Mal-LHRH 针对三阴性乳腺癌的治疗剂量和靶向疗效。
PLoS One. 2023 Oct 10;18(10):e0287151. doi: 10.1371/journal.pone.0287151. eCollection 2023.
3
Gonadotropin-releasing hormone receptor inhibits triple-negative breast cancer proliferation and metastasis.

本文引用的文献

1
Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125.三阴性乳腺癌表达促黄体激素释放激素(LHRH)受体,是细胞毒性LHRH类似物AEZS 108和AEZS 125的潜在治疗靶点。
BMC Cancer. 2014 Nov 19;14:847. doi: 10.1186/1471-2407-14-847.
2
Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study.黄体生成素释放激素激动剂对现代辅助乳腺癌化疗后卵巢功能的影响:GBG 37 ZORO 研究。
J Clin Oncol. 2011 Jun 10;29(17):2334-41. doi: 10.1200/JCO.2010.32.5704. Epub 2011 May 2.
3
促性腺激素释放激素受体抑制三阴性乳腺癌的增殖和转移。
J Int Med Res. 2022 Mar;50(3):3000605221082895. doi: 10.1177/03000605221082895.
4
The Role of Gonadotropin-Releasing Hormone (GnRH) in Endometrial Cancer.促性腺激素释放激素(GnRH)在子宫内膜癌中的作用。
Cells. 2021 Feb 1;10(2):292. doi: 10.3390/cells10020292.
5
Synthesis of Radiolabeled Technetium- and Rhenium-Luteinizing Hormone-Releasing Hormone (Tc/Re-Acdien-LHRH) Conjugates for Targeted Detection of Breast Cancer Cells Overexpressing the LHRH Receptor.用于靶向检测过表达促黄体生成素释放激素(LHRH)受体的乳腺癌细胞的放射性标记锝和铼促黄体生成素释放激素(Tc/Re-Acdien-LHRH)缀合物的合成。
ACS Omega. 2021 Jan 8;6(3):1846-1856. doi: 10.1021/acsomega.0c03991. eCollection 2021 Jan 26.
6
Enhanced Immunotherapy with LHRH-R Targeted Lytic Peptide in Ovarian Cancer.促黄体激素释放激素受体靶向溶瘤肽增强卵巢癌免疫治疗。
Mol Cancer Ther. 2020 Nov;19(11):2396-2406. doi: 10.1158/1535-7163.MCT-20-0030. Epub 2020 Sep 17.
7
Novel Crizotinib-GnRH Conjugates Revealed the Significance of Lysosomal Trapping in GnRH-Based Drug Delivery Systems.新型克唑替尼-促性腺激素释放激素缀合物揭示了溶酶体捕获在基于促性腺激素释放激素的药物递送系统中的重要性。
Int J Mol Sci. 2019 Nov 8;20(22):5590. doi: 10.3390/ijms20225590.
8
Small molecule targeted NIR dye conjugate for imaging LHRH receptor positive cancers.用于成像促黄体生成素释放激素(LHRH)受体阳性癌症的小分子靶向近红外染料偶联物。
Oncotarget. 2019 Jan 4;10(2):152-160. doi: 10.18632/oncotarget.26520.
Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines.
联合治疗:聚合物-药物偶联物作为抗癌纳米药物的机遇与挑战。
Adv Drug Deliv Rev. 2009 Nov 12;61(13):1203-13. doi: 10.1016/j.addr.2009.05.006. Epub 2009 Aug 20.
4
Peptide-based probes for cancer imaging.用于癌症成像的肽基探针。
J Nucl Med. 2008 Nov;49(11):1735-8. doi: 10.2967/jnumed.108.053041. Epub 2008 Oct 16.
5
Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study.用60Cu-ATSM正电子发射断层扫描检测肿瘤缺氧作为直肠癌新辅助放化疗患者反应和生存的预测指标:一项初步研究。
Dis Colon Rectum. 2008 Nov;51(11):1641-8. doi: 10.1007/s10350-008-9420-3. Epub 2008 Aug 6.
6
Molecular-genetic imaging based on reporter gene expression.基于报告基因表达的分子遗传成像。
J Nucl Med. 2008 Jun;49 Suppl 2:164S-79S. doi: 10.2967/jnumed.107.045955.
7
Tumor receptor imaging.肿瘤受体显像
J Nucl Med. 2008 Jun;49 Suppl 2:149S-63S. doi: 10.2967/jnumed.107.045963.
8
Multimodality molecular imaging of tumor angiogenesis.肿瘤血管生成的多模态分子成像
J Nucl Med. 2008 Jun;49 Suppl 2:113S-28S. doi: 10.2967/jnumed.107.045922.
9
Development of novel 68Ga- and 18F-labeled GnRH-I analogues with high GnRHR-targeting efficiency.开发具有高促性腺激素释放激素受体靶向效率的新型68Ga和18F标记的促性腺激素释放激素-I类似物。
Bioconjug Chem. 2008 Jun;19(6):1256-68. doi: 10.1021/bc800058k. Epub 2008 May 30.
10
Functional characterization of genetically labeled gonadotropes.基因标记促性腺激素细胞的功能特性
Endocrinology. 2008 Jun;149(6):2701-11. doi: 10.1210/en.2007-1502. Epub 2008 Mar 6.